Laura C Coates1, Andrew G Bushmakin2, Oliver FitzGerald3, Dafna D Gladman4, Lara Fallon5, Joseph C Cappelleri2, Ming-Ann Hsu2, Philip S Helliwell6. 1. University of Oxford, Oxford, UK. 2. Pfizer Inc, Groton, CT, USA. 3. Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland. 4. University of Toronto, Toronto, ON, Canada. 5. Pfizer Inc, Kirkland, QC, Canada. 6. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 2nd Floor Chapel Allerton Hospital, Chapeltown Road, Leeds, LS7 4SA, UK. p.helliwell@leeds.ac.uk.
Abstract
BACKGROUND: In psoriatic arthritis (PsA), further understanding of the relationships between clinical measures and patient-reported outcomes (PROs) is needed. This post hoc analysis evaluated associations between minimal disease activity (MDA) as a continuous outcome (termed ScoreMDA) or Psoriatic Arthritis Disease Activity Score (PASDAS) with selected PROs not included in the composite measures. METHODS: Data from two phase 3 studies of tofacitinib in PsA (OPAL Broaden [NCT01877668; N = 422]; OPAL Beyond [NCT01882439; N = 394]) were included. MDA (binary outcome) was defined as meeting ≥5/7 criteria. For ScoreMDA, each criterion was assigned a value (1 = true; 0 = false; score range, 0-7; scores ≥5 indicated MDA). For PASDAS (score range, 0-10), higher scores indicated worse disease activity. PROs analyzed included Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Patient's Assessment of Arthritis Pain visual analog scale (Pain VAS), and EuroQoL-Five Dimensions-Three Level Health Questionnaire visual analog scale (EQ-5D-3L VAS) and utility index. Relationships were evaluated using repeated measures regression models. RESULTS: Similar, approximately linear relationships were confirmed between PASDAS or ScoreMDA and PROs in both studies. In OPAL Broaden and OPAL Beyond, a one-point difference in PASDAS was associated with clinically relevant differences in PROs, including EQ-5D-3L VAS (- 6.7 mm, - 6.9 mm), Pain VAS (9.9 mm, 10.7 mm), and FACIT-F (- 2.8, - 3.3). A one-point difference in ScoreMDA was associated with clinically relevant differences in PROs, including EQ-5D-3L VAS (5.0 mm, 5.5 mm) and FACIT-F (1.9, 2.7) in OPAL Broaden and OPAL Beyond, respectively. CONCLUSIONS: Linear associations between PASDAS or ScoreMDA and PROs provide interpretable and quantifiable metrics between composite clinical measures and PROs, highlighting the importance of these measures in understanding the relevance of treat-to-target goals in PsA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01877668 . Registered on June 12, 2013. ClinicalTrials.gov, NCT01882439 . Registered on June 18, 2013.
BACKGROUND: In psoriatic arthritis (PsA), further understanding of the relationships between clinical measures and patient-reported outcomes (PROs) is needed. This post hoc analysis evaluated associations between minimal disease activity (MDA) as a continuous outcome (termed ScoreMDA) or Psoriatic Arthritis Disease Activity Score (PASDAS) with selected PROs not included in the composite measures. METHODS: Data from two phase 3 studies of tofacitinib in PsA (OPAL Broaden [NCT01877668; N = 422]; OPAL Beyond [NCT01882439; N = 394]) were included. MDA (binary outcome) was defined as meeting ≥5/7 criteria. For ScoreMDA, each criterion was assigned a value (1 = true; 0 = false; score range, 0-7; scores ≥5 indicated MDA). For PASDAS (score range, 0-10), higher scores indicated worse disease activity. PROs analyzed included Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Patient's Assessment of Arthritis Pain visual analog scale (Pain VAS), and EuroQoL-Five Dimensions-Three Level Health Questionnaire visual analog scale (EQ-5D-3L VAS) and utility index. Relationships were evaluated using repeated measures regression models. RESULTS: Similar, approximately linear relationships were confirmed between PASDAS or ScoreMDA and PROs in both studies. In OPAL Broaden and OPAL Beyond, a one-point difference in PASDAS was associated with clinically relevant differences in PROs, including EQ-5D-3L VAS (- 6.7 mm, - 6.9 mm), Pain VAS (9.9 mm, 10.7 mm), and FACIT-F (- 2.8, - 3.3). A one-point difference in ScoreMDA was associated with clinically relevant differences in PROs, including EQ-5D-3L VAS (5.0 mm, 5.5 mm) and FACIT-F (1.9, 2.7) in OPAL Broaden and OPAL Beyond, respectively. CONCLUSIONS: Linear associations between PASDAS or ScoreMDA and PROs provide interpretable and quantifiable metrics between composite clinical measures and PROs, highlighting the importance of these measures in understanding the relevance of treat-to-target goals in PsA. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01877668 . Registered on June 12, 2013. ClinicalTrials.gov, NCT01882439 . Registered on June 18, 2013.
Authors: Laura C Coates; Peter Nash; Tore K Kvien; Laure Gossec; Philip J Mease; Lawrence Rasouliyan; Luminita Pricop; Steffen M Jugl; Kunal K Gandhi; Corine Gaillez; Josef S Smolen Journal: Semin Arthritis Rheum Date: 2020-05-15 Impact factor: 5.532
Authors: Jeanie Z Fei; Anthony V Perruccio; Justine Y Ye; Dafna D Gladman; Vinod Chandran Journal: Rheumatology (Oxford) Date: 2020-01-01 Impact factor: 7.580
Authors: Alberto Cauli; Dafna D Gladman; Alessandro Mathieu; Ignazio Olivieri; Giovanni Porru; Paul P Tak; Claudia Sardu; Ilona Ujfalussy; Raffaele Scarpa; Antonio Marchesoni; William J Taylor; Antonio Spadaro; Jose L Fernàndez-Sueiro; Carlo Salvarani; Joachim R Kalden; Ennio Lubrano; Sueli Carneiro; Francesca Desiati; John A Flynn; Salvatore D'Angelo; Alessandra Vacca; Arno W R VAN Kuijk; Maria Grazia Catanoso; Mathias Gruenke; Rosario Peluso; Wendy J Parsons; Nicola Ferrara; Paolo Contu; Philip S Helliwell; Philip J Mease Journal: J Rheumatol Date: 2011-02-15 Impact factor: 4.666
Authors: Philip J Mease; Arthur Kavanaugh; Laura C Coates; Iain B McInnes; Maja Hojnik; Ying Zhang; Jaclyn K Anderson; Alexander P Dorr; Dafna D Gladman Journal: RMD Open Date: 2017-07-18
Authors: Peter Nash; Laura C Coates; Alan J Kivitz; Philip J Mease; Dafna D Gladman; José A Covarrubias-Cobos; Oliver FitzGerald; Dona Fleishaker; Cunshan Wang; Joseph Wu; Ming-Ann Hsu; Sujatha Menon; Lara Fallon; Ana Belén Romero; Keith S Kanik Journal: Rheumatol Ther Date: 2020-06-06